Effect of Transcutaneous Electrical Acupoint Stimulation on Dyspareunia

NANot yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

May 30, 2025

Conditions
Dyspareunia (Female)
Interventions
OTHER

Topical medication

It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.

OTHER

Transcutaneous electrical acupoint stimulation

This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)

Trial Locations (1)

12511

Faculty of Physical Therapy, Giza

All Listed Sponsors
lead

Cairo University

OTHER

NCT06730776 - Effect of Transcutaneous Electrical Acupoint Stimulation on Dyspareunia | Biotech Hunter | Biotech Hunter